Skip to main content
Equibles
LUCD logo

LUCD · Lucid Diagnostics Inc. · Metrics

Track LUCD — free

Use LUCD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LUCD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.41 +0.08 (+25.42%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 12, 2026
Market Cap
$66.60M
Shares
203.24M
Volume · Oct 23 111.26M Avg daily vol (3M) 3.9M

LUCD metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.41
Market cap
$66.60M

Price action

20 metrics
Price change (1W)
-14.0%
Price change (30D)
-51.0%
Price change (3M)
-54.7%
Price change (6M)
-61.6%
Price change (YTD)
-62.3%
Price change (1Y)
-66.6%
Trailing year
Price change (5Y)
-96.2%
52-week high
$1.47
52-week low
$0.33
Change from 52-week high
-72.0%
Change from 52-week low
+25.4%
Annualized volatility
71.6%
Annualized volatility (3M)
94.9%
Beta
1.2
RSI (14D)
30.3
Price vs SMA 50
-46.6%
Price vs SMA 200
-60.6%
Avg volume (3M)
3.90M
Relative volume
28.5
Average dollar volume
$1.99M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
203.24M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
12.2×
reciprocal yield 8.2%
P / book
6.1
reciprocal yield 16.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-78.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
27.7×
reciprocal yield 3.6%
EV / revenue historical average (5Y)
27.7×
reciprocal yield 3.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
-41.7%
Operating margin
-930.8%
Trailing 12 months
Net margin
-959.8%
Gross profit (TTM)
−$1.18M
Operating profit (TTM)
−$50.68M
Net income (TTM)
−$52.26M
Trailing 12 months
Diluted EPS (TTM)
$-0.87
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.08

Growth

11 metrics
Revenue growth YoY
+26.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.45M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+114.7%
Year over year · more shares
Revenue CAGR (3Y)
+132.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-478.3%
Return on assets
-134.2%
Debt / equity
2.2
Current ratio
1.3
EBITDA (TTM)
−$49.81M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
-2,981.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$47.33M
Total assets
$38.95M
Total debt
$23.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$46.87M
Capital expenditures (TTM)
$315,000
R&D (TTM)
$5.39M
SG&A (TTM)
$21,000
Stock compensation (TTM)
$4.38M
R&D / revenue
99.0%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
116
13F filer change QoQ
+13
Institutional ownership
30.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.5%
Private-fund adviser ownership
10.4%
Active holders' share change QoQ
+102.6%
Holder tenure
6.4
Price vs estimated holder cost
-6.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.7%

Short interest

3 metrics
Short interest
6.6%
Latest settlement · 10.3 days to cover
Days to cover
10.3d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1799011 CUSIP 54948X109 13F (30d) 15 filings 15 filers Visit website Investor relations